- Home
- HOST vs CURX Comparison
HOST vs CURX Comparison
Compare HOST & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOST | CURX |
|---|---|---|
| Founded | 2025 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5M | 7.5M |
| IPO Year | 2023 | 2024 |
Fundamental Metrics
Financial Performance| Metric | HOST | CURX |
|---|---|---|
| Price | $2.42 | $4.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 448.5K | 20.0K |
| Earning Date | 11-03-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,205,678.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.74 | N/A |
| 52 Week Low | $1.48 | $0.21 |
| 52 Week High | $8.99 | $16.93 |
Technical Indicators
Market Signals| Indicator | HOST | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 21.02 | 56.11 |
| Support Level | $1.48 | $3.79 |
| Resistance Level | $8.27 | $5.29 |
| Average True Range (ATR) | 0.51 | 0.50 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 45.12 | 61.72 |
Price Performance
Historical ComparisonAbout HOST Host Digital Inc.
Host Digital Infrastructure LLC is a U.S.-based infrastructure company focused on the development and operation of power-intensive data centers designed to support high-performance computing workloads, including artificial intelligence, data processing, and other compute-intensive applications. The company focuses on securing power resources and deploying computing capacity in regions across the United States.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.